科斯图诺利德通过抑制NET形成来降低DN炎症反应和脏血栓症
Xiangjing Wang1, Lina Zhang2, Ke Huang1
1Department of Nephrology, Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing, China.
Journal of diabetes research
|July 25, 2025
概括
库斯图诺利德 (COS) 通过减少炎症和血栓形成,有效地治疗小鼠的糖尿病病 (DN). 它抑制中性粒细胞外陷 (NET) 的形成,为DN管理提供治疗潜力.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病病 (DN) 是糖尿病的严重并发症,其特点是炎症,氧化应激和血栓形成.
- 中性细胞外细胞陷 (NETs) 通过促进炎症和血栓形成,在DN病变发生中发挥着关键作用.
- 考斯图诺利德 (COS) 正在研究其对DN的潜在治疗作用.
研究的目的:
- 在糖尿病病 (DN) 的小鼠模型中评估costunolide (COS) 的治疗疗效.
- 通过抑制NET形成,阐明COS在减轻炎症和血栓形成中的作用机制.
主要方法:
- 建立了一个DN小鼠模型,使用高糖,高脂肪饮食和链毒素 (STZ).
- 用不同剂量的COS治疗DN小鼠,并评估功能和病理学.
- 利用转录基因分析,免疫光,西斑和ELISA来评估炎症标志物,血小板激活和NET形成.
- 通过评估COS对隔离中性粒细胞和NET形成的影响,在体外验证了这些发现.
主要成果:
- 在DN小鼠中,COS治疗显著改善了功能,并减少了组织病理损伤.
- COS调节了参与炎症,补充和凝固级流以及NET形成的关键途径.
- COS显著降低了炎症标志物 (IL-1β,IL-6,TNF-α,CCL2),血小板激活标志物 (CD41) 和与NET相关的蛋白质 (MPO,CitH3,PAD4等). ) 的情况.
- 实验室研究证实,COS显著抑制了中性粒细胞外细胞陷 (NET) 的形成.
结论:
- 库斯图诺利德 (COS) 有效地减轻糖尿病脏病 (DN) 的小鼠的炎症和血小板激活介导的血栓形成.
- COS通过抑制过度的中性粒细胞外细胞陷 (NET) 形成来发挥其治疗作用.
- 在治疗糖尿病病 (DN) 方面,COS显示出显著的治疗潜力.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
911
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
911
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Renal Failure: Dose Adjustments
161
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
161


